What Lymphoma Coalition does

Lymphoma Coalition is a Canadian-incorporated non-profit and global patient advocacy network focused on lymphoma and chronic lymphocytic leukemia (CLL). Founded in 2002 by four lymphoma organizations and incorporated as a not-for-profit in 2010, it functions as a central hub connecting over 90 patient member organizations across 55 countries. Its core "products" are information assets and programs rather than commercial software: a biennial Global Patient Survey on Lymphomas & CLL, country-level Global Report Cards, a searchable Resource Library of 4,000+ articles, a Clinical Trial Search tool, a Treatment Database, a Lymphoma Subtypes Information Library covering B-cell and T-cell lymphomas, and dedicated hubs on CAR-T therapy, Genetic Markers, Biosimilars, and Psychosocial Effects. The organization also publishes policy resources including Health Technology Assessment (HTA) materials, the Lymphoma Patient Charter, the Global Health Expenditure Report 2024, and runs the annual World Lymphoma Awareness Day campaign plus the Karen Van Rassel Leadership Award.

The business model is that of a non-profit coalition rather than a commercial enterprise. LC is funded through a mix of sources typical of patient advocacy organizations (pharmaceutical unrestricted educational grants, member dues, donations, and partnerships), and revenue figures are not publicly disclosed. It has a small paid staff (1–10 employees) and is led by CEO Lorna Warwick until her December 2026 retirement; other named leaders include Natacha Bolaños (Head, Membership & Alliance) and Kathryn Perry (Head, Communications & Information). Its customer base is two-sided: member patient organizations (the primary institutional customers and channel partners) and individual patients affected by lymphoma, with secondary audiences of healthcare professionals, researchers, and policy advocates. Geographic reach is explicitly global, with active operations in Europe, Asia Pacific, North America, Latin America, and Africa, and a regional substructure for Lymphoma Coalition Europe.

Recent strategic emphasis has been on deepening clinical and policy relevance: LC supported the formation of Women in Lymphoma (WiL) in 2019, facilitated the 2021 merger of France Lymphome Espoir and SILLC into ELLyE, and announced a strategic partnership with WiL in June 2026 to combine its patient advocacy network with WiL's clinician/researcher community. As an independent non-profit with no parent company, no private equity ownership, and no public listing, governance rests with a Board of Directors, and the organization is currently conducting a global CEO search.

Name

Lymphoma Coalition

Legal name

Lymphoma Coalition

Website

https://lymphomacoalition.org

Company type

Private

Founded year

2002

Operating status

Operating

Headcount range

1–10 employees

Short description

Lymphoma Coalition is a Canadian non-profit global network of over 90 patient member organizations across 55 countries, providing lymphoma and CLL patient education, advocacy, research, and policy resources since 2002.

Ownership category

akta.pro rank

Product category

Patient Advocacy and Healthcare Non-Profit Services

NAICS

Other Individual and Family Services (624190), Social Advocacy Organizations (8133), Other Social Advocacy Organizations (813319)

SIC

Services-Social Services (8300), Services-Health Services (8000), Services-Membership Organizations (8600)

akta.pro primary industry

Rare Disease & Special Needs Support Organizations (BPAGACAM)

akta.pro secondary industry

Global Health Advocacy, Policy & Rights Organizations (HLAJAKAO)

Keywords

• Patient advocacy network
• Lymphoma research
• Cancer support services
• Healthcare education resources
• Nonprofit patient organization

Headquarters

HQ city

Mississauga

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Distribution channels1 record

Marketing channels1 record

Core offering

Lymphoma Coalition is a worldwide not-for-profit network of more than 90 lymphoma patient organisations across 55 countries that delivers patient education, advocacy, research, and information-sharing resources for people affected by lymphoma and chronic lymphocytic leukemia (CLL). Its core deliverables include the Global Patient Survey, Global Report Cards, Health Literacy and Health Technology Assessment resources, a CAR-T Information Hub, Genetic Markers research, Psychosocial Effects resources, the Lymphoma Patient Charter, the World Lymphoma Awareness Day campaign, Special Reports, a Lymphoma Subtypes Information Library, a Resource Library of 4,000+ articles, and Clinical Trial and Treatment search tools.

Product overview

Lymphoma Coalition operates as a global patient advocacy network rather than a technology company with commercial products. Its core offerings include the Global Patient Survey research program, Global Report Cards for country-level assessments, Health Literacy and HTA resources, and an extensive Lymphoma Subtypes Information Library covering B-cell and T-cell lymphomas. Additional offerings include CAR-T information hubs, Genetic Markers research, Psychosocial Effects resources, and the annual World Lymphoma Awareness Day campaign. The organization provides searchable Resource Library (4,000+ articles), Clinical Trial Search, and Treatment Database tools, alongside member organization networking (90+ organizations across 55 countries), Special Reports publications, Leadership Awards, and the Lymphoma Patient Charter advocacy document.

Differentiator

Problem solved

Functional benefit

Products and services

• Global Patient Survey on Lymphomas & CLL Biennial cross-sectional survey program capturing lived experiences of patients with lymphoma and CLL across multiple countries, producing data for research publications and advocacy use by member organisations, clinicians, and policy makers.
• Global Report Cards Country-level assessments measuring lymphoma and CLL outcomes, healthcare system performance, and patient access to care, used by advocates and policy stakeholders.
• Health Literacy Resources Educational materials and research focused on patient understanding of medical information, treatment options, and disease management.
• Health Technology Assessment (HTA) Resources Resources and information on Health Technology Assessment systems for medicines and emerging biotherapeutic products in the lymphoma treatment landscape, aimed at advocates and policy stakeholders.
• CAR-T Information Hub Educational resources about CAR T-cell therapy for lymphoma and CLL patients, including treatment information and research.
• Genetic Markers in Lymphoma Research Research initiative exploring genetic markers and molecular profiling in lymphoma diagnosis and treatment.
• Psychosocial Effects Resources Resources addressing fear of cancer recurrence, quality of life, fatigue, and psychological support for lymphoma patients and care partners.
• Lymphoma Patient Charter Document outlining the rights and expectations of lymphoma patients in their care journey, used by member organisations for advocacy.
• World Lymphoma Awareness Day Annual global awareness campaign to educate the public about lymphoma symptoms, diagnosis, and treatment.
• Karen Van Rassel Leadership Award Award recognizing exceptional leadership in the lymphoma patient advocacy community.
• Special Reports In-depth research publications addressing specific topics in lymphoma care, treatment access, and patient outcomes.
• Lymphoma Subtypes Information Library Comprehensive resources covering B-cell lymphomas (Burkitt, CLL, Cutaneous, DLBCL, Follicular, Hodgkin, Mantle Cell, Marginal Zone, Waldenström) and T-cell lymphomas (Peripheral T-Cell).
• Member Organization Network A network of over 90 patient organisations across 55 countries providing local support and resources to lymphoma patients and a shared information hub for member organisations.
• Resource Library Searchable library containing over 4,000 articles on scientific advances in research, treatments, and patient care.
• Clinical Trial Search Tool allowing users to find clinical trial availability by country, therapy, and lymphoma subtype.
• Treatment Database Searchable database of lymphoma treatments organized by therapy name, country, and lymphoma subtype.

Segments1 record

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• Patient Member OrganisationscoreStrategic or Co-development PartnerLymphoma Coalition serves as a worldwide network of patient organisations focused on lymphoma and chronic lymphocytic leukemia (CLL). Member organisations collaborate on patient education, advocacy, and support initiatives globally.

Scale indicators1 record

Recent moves12 records

Expansion highlights5 records

Emerging players

• Worldwide Cancer Research: Worldwide Cancer Research is a UK-based global non-profit funding cancer research across all cancer types. Comparable to Lymphoma Coalition as a global cancer non-profit, though focused on research funding rather than patient advocacy and support.
• Cancer Research Institute: Cancer Research Institute is a US-based non-profit advancing immunotherapy research, with significant relevance to lymphoma CAR-T advocacy. Comparable to Lymphoma Coalition's emerging-therapy focus (CAR-T information hub) though primarily research rather than patient support oriented.
• European Cancer Patient Coalition (ECPC): ECPC is a European umbrella organization representing cancer patient associations across Europe, including lymphoma. Comparable to Lymphoma Coalition as a multi-country patient advocacy network, though broader in cancer scope and overlapping in European coverage.

Broad incumbents

• American Cancer Society: American Cancer Society is a broad incumbent US cancer advocacy non-profit covering all cancer types including lymphoma. Comparable to Lymphoma Coalition as a patient support and advocacy organization but operating at far greater scale across all cancers.
• The Leukemia & Lymphoma Society (LLS): LLS is the largest US-based patient advocacy non-profit dedicated to blood cancers including lymphoma and CLL. It is comparable to Lymphoma Coalition as the most established direct-comparable peer in the same disease area with broader scope and significantly larger scale.

Direct peers

• Myeloma Patients Europe (MPE): Myeloma Patients Europe is a European patient advocacy network for myeloma, a closely adjacent blood cancer to lymphoma. Comparable to Lymphoma Coalition in operating model (network of national patient organizations across Europe) and disease-adjacent scope.
• Lymphoma Research Foundation (LRF): LRF is a US-based non-profit focused exclusively on lymphoma research and patient education. It is the closest direct peer to Lymphoma Coalition in disease focus, patient support mission, and research-funding activity, though primarily serving the US market.
• CLL Society: CLL Society is a US-based patient advocacy organization dedicated specifically to chronic lymphocytic leukemia — a core disease within Lymphoma Coalition's scope. Highly comparable as a disease-specific patient advocacy peer, though narrower in lymphoma-subtype coverage.
• International Myeloma Foundation: The International Myeloma Foundation is a global patient advocacy organization for myeloma, a related blood cancer. Comparable to Lymphoma Coalition in disease-specific patient advocacy mission, global footprint, and treatment-focused education.

Others

• European Hematology Association (EHA): EHA is a Europe-based professional hematology organization representing clinicians and researchers in blood disorders including lymphoma. Comparable as a hematology ecosystem stakeholder that LC engages with, but operating as a professional society rather than a patient organization.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/lymphomacoalition
• LinkedInlinkedin.com/company/lymphoma-coalition
• Xx.com/knowyournodes

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lymphoma Coalition